Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Moez Elloumi.
Bone Marrow Transplantation | 2005
Abderrahman Abdelkefi; Lamia Torjman; N Ben Romdhane; Saloua Ladeb; H El Omri; T Ben Othman; Moez Elloumi; Hatem Bellaj; Amel Lakhal; R. Jeddi; Lamia Aissaoui; Ali Saad; M. Hsairi; Kamel Boukef; Koussay Dellagi; A. Ben Abdeladhim
Summary:Thalidomide–dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line therapy, thalidomide and dexamethasone were administered for 75 days (200 mg/day) and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m2/day for 4 days, with cycles repeated on days 9 to 12 and 17 to 20 on the first and the third month of therapy. After first-line therapy, a collection of peripheral blood stem cells (PBSC) was performed. Between May 2003 and September 2004, 60 patients were included. On an intent-to-treat basis, the overall response (⩾partial response) rate was 74%, including 24% of patients who obtained a complete remission. Grade 3–4 toxicities consisted of infections (12%), deep-vein thrombosis (3%), constipation (5%), and neuropathy (5%). A total of 58 patients (96%) proceeded to PBSC mobilisation and yielded a median number of 8 × 106 CD34+ cells/kg. First-line thalidomide–dexamethasone therapy is effective and relatively well tolerated in young patients with symptomatic multiple myeloma. This combination does not affect PBSC mobilisation.
Hematological Oncology | 2008
Abir Gmidène; Hlima Sennana; Hatem Elghezal; Sihem Ziraoui; Yosra Ben Youssef; Moez Elloumi; Lamia Issaoui; Imed Harrabi; Sophie Raynaud; Ali Saad
Genetic changes associated with Acute Lymphoblastic Leukaemia (ALL) provide diagnostic and prognostic information with a direct impact on patient management. We report the cytogenetic analysis of 298 Tunisian patients with ALL, including 183 children and 115 adults. Chromosome abnormalities have been detected in 68.2% of our patients associating clonal numerical and/or structural rearrangements. Some chromosomal abnormalities especially hyperdiploidy, 19p13 abnormalities, 8q24 translocations, 12p, 6q deletions and TCR rearrangements occur at a lower incidence compared to that reported in other populations. ALL cases (5.7%) had miscellaneous clonal abnormalities. We also found in our Tunisian series a higher incidence for T‐lineage ALL more than usually described. Among structural chromosomal abnormalities, t(9;22)(q34;q11) resulting in the BCR/ABL fusion and the t(12;21)(p13;q22) resulting in the TEL/AML1 fusion were studied by FISH providing additional diagnostic and prognostic information. We conclude that although the incidence of our cytogenetic results are slightly different, their clinical significance is similar to that described in the literature. Copyright
Annales De Genetique | 2002
Halima Sennana Sendi; Hatem Elghezal; Henda Temmi; Haifa Hichri; Moez Gribaa; Halima Elomri; Belkiss Meddeb; Tarek Ben Othmane; Moez Elloumi; Ali Saad
This paper presents the results of a cytogenetic analysis in 139 Tunisian patients with de novo acute myeloid leukemia (AML), including 27 children aged 1-15 years and 112 adults. Mean age was 32 (range 1-75) and the M/F ratio was 1.43. Of our patients, 45% had apparently normal karyotypes. Acquired chromosome aberrations were found in 77 (55% ) patients. t(8;21) was identified in 27 patients (19%); t(15;17) in 13 patients (9%); deletion 7q or monosomy 7 in seven patients (5%); +8 in seven patients (5%); abnormal 16 in four patients (3%); 11q23 rearrangements in two patients (2%) and del(5q), in one patient (1%). The remaining 16 patients had miscellaneous clonal abnormalities. Specific translocations associated with the FAB type were found: t(8;21) with AML2 and t(15;17) with AML3. We concluded that our study in a Tunisian population confirmed the relation between some specific abnormalities and the FAB classification. We found a higher incidence for t(8;21) than usually described.
Bone Marrow Transplantation | 2009
Abderrahman Abdelkefi; Lamia Torjman; N Ben Romdhane; Saloua Ladeb; H El Omri; T Ben Othman; Moez Elloumi; Hatem Bellaj; Amel Lakhal; R. Jeddi; Lamia Aissaoui; Ali Saad; M. Hsairi; Kamel Boukef; Koussay Dellagi; A. Ben Abdeladhim
First-line thalidomide–dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma
Pathologie Biologie | 2011
C. Maktouf; A. Bounemra; S. Mahjoub; Fahmi Msadek; A. Khlif; M. Karoui; S. Hdiji; S. Zriba; N. Ben Romdhane; Moez Elloumi
The aim of this prospective study was to investigate the involvement of angiogenesis in the etiopathogenesis of the different classes of erythrocytosis (polycythemia vera PV, idiopathic erythrocytosis and secondary erythrocytosis). The angiogenic activity was evaluated by the assessment of the serum VEGF levels in 78 untreated erythrocytosis patients and 21 healthy subjects. The results indicated that VEGF was overproduced in advanced and untreated PV patients and at less degree, in early PV, a subgroup of idiopathic erythrocytosis, thus confirming an increased angiogenic activity. However, VEGF does not play an angiogenic role in secondary erythrocytosis.
Annales De Genetique | 2002
Halima Sennana Sendi; Haifa Hichri; Hatem Elghezal; Moez Gribaa; Adnène Laatiri; Moez Elloumi; Raihane Ben Lakhal; Ali Saad
Cytogenetic studies were performed on 117 Tunisian patients with de novo myelodysplastic syndromes (MDS). According to the French-American-British (FAB) criteria 40 patients presented with refractory anaemia (RA, 34%), eight with refractory anaemia with ringed sideroblasts (RARAS, 7%), 19 with refractory anaemia with excess of blasts (RAEB, 16%), 16 with refractory anaemia with excess of blasts in transformation (RAEB-t, 14%), 18 had chronic myelomonocytic leukaemia (CMML, 15%) and 16 unclassifiable MDS (14%). Seventy-five were men and forty-two were women. Five were children and 112 were adults with a median age of 58 years. Fifty-five per cent of the patients presented clonal chromosome abnormalities. Rates of abnormality varied from one FAB subtype to the other: 55% in RA, 75% in RARAS, 63% in RAEB, 75% in RAEB-t and 28% in CMML. The most frequent chromosome abnormalities were del(5q) (22 cases), monosomy 7 (12 cases), del(12p) (6 cases), and trisomy 8 (5 cases). Rare abnormalities were also found: ring of chromosome 12 and trisomy 15. Conventional cytogenetics remains the basic technique in identifying chromosomal abnormalities associated with MDS.
Blood | 2008
Abderrahman Abdelkefi; Saloua Ladeb; Lamia Torjman; Tarek Ben Othman; Amel Lakhal; Neila Ben Romdhane; Halima El Omri; Moez Elloumi; Hatem Belaaj; Ramzi Jeddi; Lamia Aissaoui; Habib Ksouri; Assia Ben Hassen; Fahmi Msadek; Ali Saad; M. Hsairi; Kamel Boukef; Ahlem Amouri; Hechmi Louzir; Koussay Dellagi; Abdeladhim Ben Abdeladhim
Blood | 2006
Abderrahman Abdelkefi; Saloua Ladeb; Tarek Ben Othman; Lamia Torjman; Amel Lakhal; Neila Ben Romdhane; Halima El Omri; Moez Elloumi; Hatem Bellaj; R. Jeddi; Lamia Aissaoui; Fahmi Msadek; Ali Saad; M. Hsairi; Kamel Boukef; Ahlem Amouri; Hechmi Louzir; Koussay Dellagi; Abdeladhim Ben Abdeladhim
Haematologica | 2010
R. Ben Amor; R. Ben Lakhal; Hela Ghedira; Hatem Belaaj; Mohamed Adnène Laatiri; Y. Ben Youssef; N. Ben Romdhane; F. Msaddek; Samia Menif; Moez Elloumi; Abderrahim Khelif; B. Meddeb
Genetic Testing | 2004
Chiraz Bouchlaka; Tarek Ben Othman; Lamia Aissaoui; Houda Elloumi; Moez Elloumi; Ahlem Amouri; Hela Ben Abid; Sondes Hadiji; Hmida Slama; Hafedh Makni; Ali Saad; Sonia Abdelhak; Koussay Dellagi